Source link : https://www.newshealth.biz/health-news/mixed-results-for-adjuvant-pembro-in-endometrial-cancer/
BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy following surgery with curative intent. In the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial, adding pembrolizumab to adjuvant chemotherapy did not improve disease-free survival in the “all-comer” intention-to-treat population. However, in prespecified subgroup analyses, […]
Author : News Health
Publish date : 2024-09-19 05:40:56
Copyright for syndicated content belongs to the linked Source.
Categories